Molecular neuro-oncology and the challenge of the blood-brain barrier

Seminars in Oncology

Volumn 41, Issue 4, 2014, Pages 438-445

  Aiken, Robert ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR; HISTONE H3; ISOCITRATE DEHYDROGENASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA; TEMOZOLOMIDE; VEMURAFENIB; BRAF PROTEIN, HUMAN; DACARBAZINE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; ASTROCYTOMA; BLOOD BRAIN BARRIER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CHEMORADIOTHERAPY; CHROMOSOME 19Q; CHROMOSOME 1P; CPG ISLAND; DNA METHYLATION; DNA REPAIR; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENOME ANALYSIS; GLIOBLASTOMA; GLIOMA; HETEROZYGOSITY LOSS; HUMAN; MOLECULAR GENETICS; NERVOUS SYSTEM TUMOR; NEUROIMAGING; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; ONCOGENE; PHENOTYPE; PILOCYTIC ASTROCYTOMA; PONTINE GLIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; CHROMOSOME DELETION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY; PROCEDURES;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CHROMOSOME DELETION; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG DELIVERY SYSTEMS; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MOLECULAR TARGETED THERAPY; PROTO-ONCOGENE PROTEINS B-RAF; TUMOR SUPPRESSOR PROTEINS;

EID: 84906765962     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2014.06.005     Document Type: Article

References (61)

1. M.R. Gilbert, J.J. Dignam, T.S. Armstrong, J.S. Wefel, D.T. Blumenthal, and M.A. Vogelbaum et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma N Engl J Med 370 2014 699 708
2. O.L. Chinot, W. Wick, W. Mason, R. Henriksson, F. Saran, and R. Nishikawa et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma N Engl J Med 370 2014 709 722
3. R. Stupp, W.P. Mason, M.J. Van Den Bent, M. Weller, B. Fisher, and M.J.B. Taphoorn et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
4. M.E. Hegi, A.C. Diserens, T. Gorlia, M.F. Hamou, N. de Tribolet, and M. Weller et al. MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 2005 997 1003
5. R. Stupp, M. Hegi, W.P. Mason, M.J. van den Bent, M.J.B. Taphoorn, and R.B. Janzer et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 2009 459 466
6. M. Weller, R. Stupp, and G. Reifenberger MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6 2010 39 51
7. V.Q. Quillen, A. Lavenue, L. Karayan-Tapon, C. Carpentier, M. Labussiere, and T. Lesimple et al. Comparative assessment of 5 methods (methylation- specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients Cancer 118 2012 4201 4211
8. A. Benner, J. Meyer, A. von Deimling, M. Weller, W. Wick, and M. Weiler Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma PLoS ONE 2012 e33449
9. L. Dang, D.W. White, S. Gross, B.D. Bennett, M.A. Bittinger, and E.M. Driggers et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 462 2009 739 744
10. H. Yan, W. Parsons, G. Jin, R. McLendon, A. Rasheed, and W. Yuan et al. IDH1 and IDH2 mutations in gliomas N Engl J Med 360 2009 765 773
11. P. Metellus, C. Berne, C. Colin, A.M. de Paula, A. Vasilevic, and D. Taieb Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis Acta Neuropathol 120 2010 719 729
12. C. Choi, S.K. Ganji, R. DeBernadinis, K.J. Hatanpaa, D. Rakheja, and Z. Kovacs et al. 2-Hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas Nat Med 18 2012 624 629
13. R.G.W. Verhaak, C.A. Hoadley, E. Purdom, V. Wang, Y. Qi, and M.D. Wilkerson et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 17 2010 98 110
14. E.G. Shaw, M. Wang, S.W. Coons, D.G. Brachman, J. Buckner, and K.J. Stelzer et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial low-grade glioma: initial results of RTOG 9802 J Clin Oncol 30 2012 3065 3070
15. M. Gupta, A. Djalilvand, and D.J. Brat Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma Am J Clin Pathol 124 2005 755 768
16. Y. Jiao, P.J. Killela, Z.J. Reitman, B.A. Rasheed, C.M. Heaphy, and R.F. de Wilde et al. Frequent ATRX, CIC, FUBP1, and IDH1 mutations refine the classification of malignant gliomas Oncotarget 3 2012 709 722
17. C. Bettegowda, N. Agrawal, Y. Jiao, M. Sausen, L.D. Wood, and R.H. Hruban et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma Science 333 2011 1453 1456
18. S. Yip, Y.S. Butterfield, O. Morozova, S. Chittaranjan, M.D. Blough, and J. An et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers J Pathol 226 2012 7 16
19. L. Erdem-Erasian, L.A. Gravdendeel, J. de Rooi, P.H.C. Eilers, A. Idbaih, and W.G.M. Spilet et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951 J Clin Oncol 31 2013 328 336
20. J.G. Cairncross, M. Wang, E. Shaw, R. Jenkins, D. Brachman, and J. Buckner et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402 J Clin Oncol 31 2013 337 343
21. J.G. Cairncross, M. Wang, R.B. Jenkins, E.G. Shaw, C. Giannini, and D.G. Brachman et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH J Clin Oncol 32 2013 783 790
22. Z. Sadighi, and J. Slopis Pilocytic astrocytoma: a disease with evolving molecular heterogeneity J Child Neurol 28 2013 625 632
23. C. Horbinski To BRAF or not to BRAF: is that even a question anymore? J Neuropathol Exp Neurol 72 2013 2 7
24. S. Dahiya, R.J. Emnett, D.H. Haydon, J.R. Leonard, J.J. Phillips, and A. Perry et al. BRAF-V600E mutation in pediatric and adult glioblastoma Neurooncology 16 2014 318 319
25. R.K. Mittapalli, S. Vaidyanathan, A.Z. Dudek, and W.F. Elmquist Mechanisms limiting distribution of the threonine-protein kinase B-raf (V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases J Pharmacol Exp Ther 344 2013 655 664
26. W. Wick, M. Platten, C. Meisner, J. Felsberg, G. Tabatabai, and M. Simon et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomized phase 3 trial Lancet Oncol 13 2012 707 715
27. A. Maimstrom, B.H. Gronberg, C. Marosi, R. Stupp, D. Frappaz, and H. Schultz et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomized, phase 3 trial Lancet Oncol 13 2012 916 926
28. J. Swartzentruber, A. Korshunov, X.Y. Liu, D.T. Jones, E. Pfaff, and K. Jacob et al. Driver mutations in histone H3.3 and chromatin remodeling genes in paediatric glioblastoma Nature 482 2012 226 231
29. D. Sturm, H. Witt, V. Hovestadt, D.A. Khuong-Quang, D.T. Jones, and C. Konermann et al. Hotspot manifestations in H3F3A and IDH1 define distinct epigenetic and biological subgroups in glioblastoma Cancer Cell 22 2012 425 437
30. G. Wu, A. Broniscer, T.A. McEachron, C. Lu, B.S. Paugh, and J. Becksfort et al. Somatic histone H3.3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas Nat Genet 44 2012 251 253
31. A.M. Fontebasso, X.Y. Liu, D. Sturm, and N. Jabado Chromatin remodeling defects in pediatric and young adult glioblastoma: a tale of a variant histone 3 tail Brain Pathol 23 2013 210 216
32. I.F. Pollack, and J.J. Mulvihill Neurofibromatosis 1 and 2 Brain Pathol 7 1997 823 836
33. A.J. Sievert, S.-S. Lang, K.L. Boucher, P.J. Madsen, E. Slaunwhite, and N. Choudhari et al. Paradoxical activation of RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytes Proc Natl Acad Sci U S A 110 2013 5957 5962
34. H.S. Friedman, and D.D. Bigner Glioblastoma multiforme and the epidermal growth factor receptor N Engl J Med 353 2005 1997 1999
35. J.H. Sampson, A.B. Heimberger, G.E. Archer, K.D. Aldape, A.H. Friedman, and M.R. Gilbert et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma J Clin Oncol 28 2010 4722 4729
36. M. Weller, K. Kaulich, B. Hentschel, J. Feisberg, D. Gramatzki, and T. Pietsch et al. Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent adjuvant temozolomide radiochemotherapy Int J Cancer 134 2014 2437 2447
37. Reardon D. Phase 2 frontline long-term overall survival assessments (ACT III, ACT II, and ACTIVATE). Oral session presentation at World Fed Neuro-oncology, November 24, 2013. Celldex Therapeutics. http://ir.celldex.com/ releasedetail.cfm?ReleaseID=809242, accessed February 15, 2014.
38. D. La Torre, A. Conti, M.H. Aguennouz, M.G. De Pasquale, S. Romeo, and F.F. Angileri et al. Telomere length modulation in human astroglial brain tumors PLoS ONE 8 5 2013 e64296
39. N. Nonoguchi, T. Ohta, J.-E. Oh, Y.-H. Kim, P. Kleihues, and H. Ohgaki TERT promoter mutations in primary and secondary glioblastomas Acta Neuropathol 126 2013 931 937
40. P.J. Killela, Z.J. Reitman, Y. Jiao, C. Bettegowda, N. Agrawal, and L.A. Diaz Jr et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal Proc Natl Acad Sci U S A 110 2013 6021 6026
41. S. Palumbo, C. Miracco, L. Pirtoli, and S. Comincini Emerging roles of microRNA in modulating cell-death processes in malignant glioma J Cell Physiol 229 2014 277 286
42. M. Signore, L. Ricci-Vitiani, and R. De Maria Targeting apoptosis pathways in cancer stem cells Cancer Lett 332 2013 374 382
43. Y. Guan, M. Mizoguchi, K. Yoshimoto, N. Hata, T. Shono, and S.O. Suzuki et al. miRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance Clin Cancer Res 16 2010 4289 4297
44. G. Gabriely, M. Yi, R.S. Narayan, J.M. Niers, T. Wurdinger, and J. Imitola et al. Human glioma growth is controlled by microRNA-10b Cancer Res 71 2011 3563 3572
45. T. Papagiannakopoulos, D. Friedmann-Morvinski, P. Neveu, J.C. Dugas, R.M. Gill, and E. Huillard et al. Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases Oncogene 31 2012 1884 1895
46. C. Yang, C. Wang, X. Chen, S. Chen, Y. Zhang, and F. Zhi et al. Identification of seven serum microRNAs from genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas Int J Cancer 132 2013 116 127
47. J. Lu, G. Getz, E.A. Miska, E. Alvarez-Saavedra, J. Lamb, and D. Peck et al. MicroRNA expression profiles classify human cancers Nature 435 2005 834 838
48. A. Odjele, D. Charest, and P. Morin Jr miRNAs as important drivers of glioblastomas: a no-brainer? Cancer Biomarkers 11 2012 245 252
49. J.J. Laterra, and G.W. Goldstein The blood-brain-barrier, choroid plexus, and cerebrospinal fluid E.R. Kandel, J.H. Schwartz, T.M. Jessell, S.A. Siegelbaum, A.J. Hundspeth, Principles of neural science 5th ed 2013 McGraw-Hill New York 1565 1572
50. F. Dyrne, S. Hanske, M. Krueger, and I. Bechmann The blood-brain-barrier J Neuroimmune Pharmacol 8 2013 763 773
51. N.A. Colabufo, F. Berardi, M. Contino, M. Niso, and R. Perrone ABC pumps and their role in active drug transport Current Top Med Chem 9 2009 119 129
52. H. Wolburg, S. Noell, P. Fallier-Becker, A.F. Mack, and K. Wolburg-Buchholz The disturbed blood-brain barrier in human glioblastoma Mol Aspects Med 33 2012 579 589
53. F. Lin, M.C. de Gooijer, D. Hanekamp, D. Brandsma, J.H. Beijnen, and O. van Tellingen Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux CNS Oncol 2 2013 271 288
54. S. Agarwal, R. Sane, J.L. Gallardo, J.R. Ohlfest, and W.F. Elmquist Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux J Pharmacol Exp Ther 334 2010 147 155
55. Y. Chen, S. Agarwal, N.M. Shaik, C. Chen, Z. Yang, and W.F. Elmquist P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib J Pharmacol Exp Ther 330 2009 956 963
56. J.S. Lagas, R.A.B. van Waterschool, VACJ van Tilburg, M.J. Hillebrand, N. Lankheet, and H. Rosing et al. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment Clin Cancer Res. 15 2009 2344 2353
57. S.C. Tang, J.S. Lagas, N.A. Lankheet, B. Poller, M.J. Hillebrand, and H. Rosing et al. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib Int J Cancer 130 2012 223 233
58. T. Wang, S. Agarwal, and W.F. Elmquist Brain distribution of cediranib is limited by active efflux at the blood-brain-barrier J Pharmacol Exp Ther 341 2012 386 395
59. R.K. Mittapalli, S. Vaidyhyanathan, R. Sane, and W.F. Elmquist Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032) J Pharmacol Exp Ther 342 2012 33 40
60. L. Zinzi, E. Capparelli, M. Cantore, M. Contino, M. Leopoldo, and N.A. Colabufo Small and innovative molecules as new strategy to revert MDR Frontiers Oncol 4 2014 1 12
61. F.M. Iwamoto, A.R. Cooper, A.S. Reiner, L. Nayak, and L.E. Abrey Glioblastoma in the elderly Cancer 115 2009 3758 3766